MARS Bioimaging Ltd spectral CT for biomedical imaging Anthony Butler

Founded 2008: Spin out of University of Canterbury Exclusive licence for CERN Medipix3 detector technology Own all IP relating spectral CT from the university Products: MARS scanners: Medipix3 based microCT system MARS camera: Medipix3 detector and readout for integration into 3 rd party CTs Overview

Technology and its uses

Xray source MARS spectral CT Medipix Color detectors Spectral CT is now possible M edipix A ll R esolution S ystem Energy resolution Spatial resolution Temporal resolution

Cartilage Bone Low GAG

MBI Products

MARS scanner microCT for small animal and pathology researcher

MARS Medipix3 camera Up to 8 Simultaneous energies 55µm or 110 µm pixel pitch resolution 1 to 6 Medipix chips (28x52mm array) Silicon or CdTe/CZT Excellent energy resolution ( Charge sharing compensation ) Image of PCB taken with Medipix3 Si-quad, 28x28mm Medipix3 camera system for integration into 3 rd party systems

MBI Company information

Market strategy Get MARS systems to key opinion leader’s labs Enable researchers using MARS tool to validate spectral CT Provide camera units for existing pre-clinical manufacturers to integrate into their systems Leverage pre-clinical adoption to find partner for human imaging

MARS project structure MARS is the technology MARS Bioimaging Ltd aka. “MBI” Commercial outlet for NZ’s R+D Research teams University of Canterbury University of Otago

MARS project structure MARS Bioimaging Ltd aka. “MBI” Commercial outlet for NZ’s R+D Shareholders University of Canterbury Individual scientist Private investors

MARS IP structure MARS Bioimaging Ltd Medipix3 Collaboration University of Canterbury University of Otago Exclusive license for small animal and human CT All IP relating to spectral CT technology Sub-contract for pre-clinical research

MARS Funding structure MARS Bioimaging Ltd Medipix3 Collaboration University of Canterbury University of Otago Investment

MARS Funding structure MARS Bioimaging Ltd Medipix3 Collaboration University of Canterbury University of Otago Investment Sales

MARS Funding structure MARS Bioimaging Ltd Medipix3 Collaboration University of Canterbury University of Otago Investment Sales Contribution to Medipix3 development Scholarship funding

MARS Funding structure MARS Bioimaging Ltd Medipix3 Collaboration University of Canterbury University of Otago Investment Sales Scholarship funding NZ government funding Contribution to Medipix3 development

Why would a researcher do this?

Government instruction 80% of NZ government funding is aimed at economic return  Key concept is international revenue  Want a route to market early in an R+D program

Benefit to research Provides direction and focus Get the technology into users hands early Provides new funding routes

Personal Satisfaction – your research is used!!! New challenges

Personal Satisfaction – your research is used!!! New challenges Potential for financial gain… …. but I’m a radiologist!!

Summary MARS-CT make spectral CT possible Early adopters already purchasing